Article

Cohesive agent performs reliably in all stages of surgery

Cataract surgeons who choose sodium hyaluronate 1.2% (StaarVisc II, STAAR Surgical) for their routine cases know they can rely on it from beginning to end to offer all the features they seek in a viscoelastic.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint
March 24th 2025

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema
March 24th 2025

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis
March 24th 2025

Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis

Bausch + Lomb publishes results from phase 4 study evaluating patient-reported outcomes with Miebo in dry eye disease
March 24th 2025

Bausch + Lomb publishes results from phase 4 study evaluating patient-reported outcomes with Miebo in dry eye disease

© 2025 MJH Life Sciences

All rights reserved.